Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
SCDS
MCID: SPR126
MIFTS: 41

Superior Semicircular Canal Dehiscence (SCDS)

Categories: Bone diseases, Ear diseases, Rare diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Superior Semicircular Canal Dehiscence

About this section

MalaCards integrated aliases for Superior Semicircular Canal Dehiscence:

Name: Superior Semicircular Canal Dehiscence 12 15
Superior Semicircular Canal Dehiscence Syndrome 12 20
Superior Canal Dehiscence Syndrome 20
Third Mobile Window Syndrome 12
Canal Dehiscence Syndrome 12
Superior Canal Dehiscence 12
Superior Canal Syndrome 12
Anemia, Sickle Cell 71
Scds 20

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Ear diseases Bone diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080193
UMLS 71 C0002895
Sources

Summaries for Superior Semicircular Canal Dehiscence

About this section
GARD : 20 Superior semicircular canal dehiscence syndrome is a rare balance disorder characterized by auditory and/or vestibular symptoms. These might include dizziness and vertigo triggered by heavy lifting, straining, coughing or loud sounds that change the middle ear or intracranial pressure, fullness in the ear, autophony (an echo or reverberation in the ear when speaking, chewing or swallowing), hearing loss, nystagmus, or oscillopsia (the apparent motion of objects that are stationary). This condition is caused by an opening (dehiscence) in the bone that overlays the superior (uppermost) semicircular canal within the inner ear. While many patients with superior semicircular canal dehiscence syndrome are able to tolerate their symptoms and reduce or avoid triggering stimuli, others can benefit from surgical repair of the dehiscence.

MalaCards based summary : Superior Semicircular Canal Dehiscence, also known as superior semicircular canal dehiscence syndrome, is related to semicircular canal dehiscence syndrome and otosclerosis, and has symptoms including angina pectoris, abdominal pain and chest pain. An important gene associated with Superior Semicircular Canal Dehiscence is HMX3 (H6 Family Homeobox 3). The drugs Deferasirox and Proguanil have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and endothelial, and related phenotype is hearing/vestibular/ear.

Disease Ontology : 12 An inner ear disease characterized by dehiscence in the bone overlying the superior semicircular canal experience with symptoms of pressure or sound-induced vertigo, bone conduction hyperacusis, and pulsatile tinnitus.

Wikipedia : 74 Superior semicircular canal dehiscence syndrome is a set of hearing and balance symptoms, related to a... more...

Sources

Related Diseases for Superior Semicircular Canal Dehiscence

About this section

Diseases related to Superior Semicircular Canal Dehiscence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Related Disease Score Top Affiliating Genes
1 semicircular canal dehiscence syndrome 31.9 NTN1 HMX3
2 otosclerosis 31.2 SLC26A4 COCH
3 meniere disease 30.8 SLC26A4 COCH
4 labyrinthitis 30.4 SLC26A4 COCH
5 vestibular disease 30.4 SLC26A4 COCH
6 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 11.0
7 pathologic nystagmus 10.8
8 sensorineural hearing loss 10.8
9 hyperacusis 10.7
10 otitis media 10.6
11 cholesteatoma of middle ear 10.4
12 encephalocele 10.4
13 deafness, autosomal dominant 9 10.4
14 allergic disease 10.4
15 ehlers-danlos syndrome 10.4
16 meningoencephalocele 10.4
17 perilymphatic fistula 10.4
18 sudden sensorineural hearing loss 10.4
19 migraine with or without aura 1 10.2
20 osteoporosis 10.2
21 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
22 aging 10.2
23 body mass index quantitative trait locus 1 10.2
24 bone mineral density quantitative trait locus 8 10.2
25 bone mineral density quantitative trait locus 15 10.2
26 agenesis of corpus callosum, cardiac, ocular, and genital syndrome 10.2
27 sleep apnea 10.2
28 fibrous dysplasia 10.2
29 b-lymphoblastic leukemia/lymphoma 10.2
30 meningocele 10.2
31 patulous eustachian tube 10.2
32 acoustic neuroma 10.2
33 facial paralysis 10.2
34 neurilemmoma 10.2
35 intracranial hypertension 10.2
36 meningitis 10.2
37 48,xyyy 10.2
38 cerebrospinal fluid leak 10.2
39 head injury 10.2
40 spontaneous intracranial hypotension 10.2
41 autosomal dominant non-syndromic sensorineural deafness type dfna 10.2
42 benign paroxysmal positional nystagmus 10.1
43 middle ear disease 10.1
44 deafness, autosomal dominant 56 10.1 SLC26A4 COCH
45 peripheral vertigo 10.1 SLC26A4 COCH
46 deafness, autosomal recessive 1a 10.0 SLC26A4 COCH
47 auditory system disease 10.0 SLC26A4 COCH
48 aphasia 10.0
49 vestibular neuronitis 10.0
50 neuritis 10.0

Comorbidity relations with Superior Semicircular Canal Dehiscence via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Superior Semicircular Canal Dehiscence:



Diseases related to Superior Semicircular Canal Dehiscence
Sources

Symptoms & Phenotypes for Superior Semicircular Canal Dehiscence

About this section

UMLS symptoms related to Superior Semicircular Canal Dehiscence:


angina pectoris, abdominal pain, chest pain, edema

MGI Mouse Phenotypes related to Superior Semicircular Canal Dehiscence:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hearing/vestibular/ear MP:0005377 8.92 COCH HMX3 NTN1 SLC26A4
Sources

Drugs & Therapeutics for Superior Semicircular Canal Dehiscence

About this section

Drugs for Superior Semicircular Canal Dehiscence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 361)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381 214348
2
Proguanil Approved Phase 4 500-92-5 4923
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
5
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
6
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
7
Desogestrel Approved Phase 4 54024-22-5 40973
8
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
9
Tocopherol Approved, Investigational Phase 4 1406-66-2
10
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
11
Iron Approved Phase 4 7439-89-6 23925 29936
12
Deferiprone Approved Phase 4 30652-11-0 2972
13
Lactitol Approved, Investigational Phase 4 585-86-4 157355
14
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
15
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
16
Ibuprofen Approved Phase 4 15687-27-1 3672
17
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
18
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
19
Dihydroartemisinin Experimental, Investigational Phase 4 71939-50-9 6918483
20
Piperaquine Experimental, Investigational Phase 4 4085-31-8 5079497
21 Tocotrienol Investigational Phase 4 6829-55-6
22 Contraceptive Agents Phase 4
23 Folic Acid Antagonists Phase 4
24 Anesthetics, General Phase 4
25 Anesthetics, Intravenous Phase 4
26 Progestins Phase 4
27
Ethylene Phase 4 74-85-1 6325
28 Hydroxycholecalciferols Phase 4
29 Artemisinine Phase 4
30 Artemisinins Phase 4
31 Hemostatics Phase 4
32 Arginine Vasopressin Phase 4
33 Vasopressins Phase 4
34 Coagulants Phase 4
35 Deamino Arginine Vasopressin Phase 4
36 Vitamins Phase 4
37 Tocotrienols Phase 4
38 Tocopherols Phase 4
39 Nutrients Phase 4
40 Micronutrients Phase 4
41 Antioxidants Phase 4
42 Trace Elements Phase 4
43 Protective Agents Phase 4
44 Chelating Agents Phase 4
45 Iron Chelating Agents Phase 4
46 Antirheumatic Agents Phase 4
47 Anti-Inflammatory Agents Phase 4
48 Anesthetics, Dissociative Phase 4
49 Analgesics, Non-Narcotic Phase 4
50 Anti-Inflammatory Agents, Non-Steroidal Phase 4

Interventional clinical trials:

(show top 50) (show all 800)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Unknown status NCT02041299 Phase 4 Deferiprone;Deferoxamine
2 Effect of Mobile-Directly Observed Therapy (DOT) on Adherence to Hydroxyurea Treatment in Adult HbSS Patients at Muhimbili National Hospital (MNH) in Tanzania: a Pilot Study Unknown status NCT02844673 Phase 4 Hydroxyurea
3 Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease Completed NCT02222246 Phase 4 Hydromorphone (Standardized, weight-based dosing);Morphine Sulfate (Standardized, weight-based dosing);Hydromorphone (Patient Specific dosing);Morphine Sulfate (Patient Specific dosing)
4 Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis: A Randomized, Double Blind Placebo Controlled Trial Completed NCT01482091 Phase 4 Fentanyl Citrate;Normal Saline
5 Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions Completed NCT02731157 Phase 4 Rejuvesol
6 Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Emergency Department Patients With Acute Sickle Cell Crises? Completed NCT03541980 Phase 4 Acetaminophen;Normal saline
7 Use of Etonogestrel-releasing Contraceptive Implant in Women With Sickle Cell Disease Completed NCT02594462 Phase 4 etonogestrel-releasing implant contraceptive
8 Evaluation of the Impact of Renal Function on the Pharmacokinetics of Hydroxyurea (SIKLOS ®) in Normal-renal Function, Hyperfiltrating and Renal Failure Sickle Cell Disease Patients (DARH) Completed NCT02522104 Phase 4 Siklos
9 Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade) Completed NCT00749515 Phase 4 Deferoxamine;Deferasirox
10 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Completed NCT03176849 Phase 4
11 Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated. Completed NCT01609192 Phase 4 Hydrea® (hydroxyurea )
12 Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) Completed NCT03178643 Phase 4 Proguanil Oral Tablet;Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ);Dihydroartemisinin-Piperaquine (DP)
13 Intranasal Fentanyl Versus Intravenous Morphine in the Emergency Department Treatment of Severe Painful Sickle Cell Crises in Children Completed NCT03682211 Phase 4 Fentanyl Citrate;Morphine sulphate
14 The Effect of Voxelotor on Exercise Capacity of Youths With Sickle Cell Anemia Recruiting NCT04581356 Phase 4 Voxelotor
15 A Phase 4, Open-Label, Single-Center Study to Assess Pharmacokinetic Characteristics and Safety of Endari in Patients With Sickle Cell Disease Recruiting NCT04684381 Phase 4 L-glutamine
16 Desmopressin as a Therapy for Nocturnal Enuresis in Pediatric Patients With Sickle Cell Disease Recruiting NCT04420585 Phase 4 Desmopressin
17 Risk Stratification for Clinical Severity of Sickle Cell Disease in Nigeria and Assessment of Efficacy and Safety During Treatment With Hydroxyurea Active, not recruiting NCT02149537 Phase 4 hydroxyurea
18 Endothelial Monocyte-activating Polypeptide-II as an Endothelial Dysfunction Marker and Its Relation to the Oxidative Stress in Egyptian Sickle Patients Active, not recruiting NCT03903133 Phase 4 Vitamin E
19 Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Enrolling by invitation NCT02443545 Phase 4 Deferiprone
20 An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Vaso-occlusive Crises. Not yet recruiting NCT04662931 Phase 4 crizanlizumab
21 Early Low-dose Ketamine Infusion Versus Usual Care for Sickle Cell Pain Crisis: a Randomized, Prospective Study. Not yet recruiting NCT04005209 Phase 4 Ketamine
22 An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study Not yet recruiting NCT04657822 Phase 4 Crizanlizumab
23 A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease Not yet recruiting NCT04400487 Phase 4 Voxelotor
24 A Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease Terminated NCT00252122 Phase 4 Ketamine
25 An Open, Multicenter Clinical Trial to Investigate the Immunogenicity and Safety of the Pneumococcal 7-Valent Conjugate Vaccine (PREVENAR) in Sickle Cell Disease Infants. Terminated NCT00368186 Phase 4
26 Ketorolac Versus Ibuprofen for the Painful Crisis of Sickle Cell Disease - Southwestern Comprehensive Sickle Cell Center Terminated NCT00115336 Phase 4 Intravenous Ketorolac;Ibuprofen
27 An Evaluation of the Effectiveness of Ibuprofen and Opioid (Morphine or Diamorphine) for Acute Pain in Sickle Cell Disease: a Double-blind, Placebo-controlled Randomised Trial Terminated NCT00880373 Phase 4 Ibuprofen;Placebo;Diamorphine or Morphine
28 Non-Invasive Assessment of Opioid Analgesia in Children With Sickle Cell Disease Withdrawn NCT00513864 Phase 4 Dextromethorphan;Codeine;Morphine
29 Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil Withdrawn NCT00937144 Phase 4 Viagra (Sildenafil);placebo
30 Omega 3 Fatty Acid Therapy for Prevention of Vaso-occlusive Crisis and Manifestations in Omani Patients With Sickle Cell Disease Unknown status NCT02525107 Phase 3
31 Development of a Ready-to-use Nutraceutical Food for Patients With Sickle Cell Disease (SCD): Testing of Vascular Support Components Unknown status NCT01718054 Phase 2, Phase 3 Chloroquine
32 A Phase 3, Prospective, Randomized, Double-Blind, Placebo Controlled, Multi-center Study of SC411 for Sickle Cell Disease Unknown status NCT02604368 Phase 3 SC411;Placebo
33 Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease, a Pilot Study Unknown status NCT02801292 Phase 3 Ketamine
34 A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload Unknown status NCT01511848 Phase 2, Phase 3 DFP (ferriprox) and deferasirox (ICL 670);DFP, DFO
35 Preventing Stroke Triggers in Children With Sickle Cell Anaemia in Mulago Hospital, Kampala (PREST ): a Randomized Control Trial Unknown status NCT03666806 Phase 2, Phase 3
36 Transfusion Alternatives Pre-Operatively in Sickle Cell Disease Unknown status NCT00512577 Phase 3
37 Ameliorating Attention Problems in Children With SCD Completed NCT01411280 Phase 3 methylphenidate
38 MAST - Magnesium for Sickle Cell Acute Crisis in Children Completed NCT00313963 Phase 3 Magnesium Sulfate;Normal Saline
39 A Phase 3, Multicenter ,Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease Completed NCT02187003 Phase 3 Rivipansel
40 Stroke Prevention in Sickle Cell Anemia (STOP 1) Completed NCT00000592 Phase 3
41 Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH) Completed NCT00000586 Phase 3 hydroxyurea
42 Penicillin Prophylaxis in Sickle Cell Disease (PROPS) Completed NCT00000585 Phase 3 penicillin
43 Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease Completed NCT00560261 Phase 3
44 A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE ß0-THALASSEMIA Completed NCT01179217 Phase 3 L-glutamine;Placebo
45 Presumptive Treatment With Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prophylaxis in Children With Sickle Cell Anemia Completed NCT00399074 Phase 3 sulfadoxine pyrimethamine
46 Hypnosis as a Pain and Symptom Management Strategy in Patients With Sickle Cell Disease Completed NCT00393250 Phase 3
47 Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathy Using a Preparative Regimen to Achieve Stable Mixed Chimerism Completed NCT00176852 Phase 2, Phase 3 Busulfan, Fludarabine, ATG, TLI;Busulfan, Cyclophosphamide, ATG, GCSF;Campath, Fludarabine, Cyclophosphamide
48 Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial Completed NCT00072761 Phase 3
49 Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease Completed NCT00004408 Phase 3 poloxamer 188
50 Choosing Opioid Management for Pain and Analyzing ACS Rates Equally Completed NCT01380197 Phase 3 Morphine;Nubain

Search NIH Clinical Center for Superior Semicircular Canal Dehiscence

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Sodium phenylbutyrate
Sources

Genetic Tests for Superior Semicircular Canal Dehiscence

About this section
Sources

Anatomical Context for Superior Semicircular Canal Dehiscence

About this section

MalaCards organs/tissues related to Superior Semicircular Canal Dehiscence:

40
Bone, Bone Marrow, Endothelial, Liver, T Cells, Kidney, Neutrophil
Sources

Publications for Superior Semicircular Canal Dehiscence

About this section

Articles related to Superior Semicircular Canal Dehiscence:

(show top 50) (show all 355)
# Title Authors PMID Year
1
Radiologically-proven New Development of Superior Semicircular Canal Dehiscence Associated With Development of Superior Semicircular Canal Dehiscence Syndrome. 61
33273305 2021
2
Analysis of temporal bone thickness outside of the petrous temporal bone between superior semicircular canal dehiscence and normal patients. 61
33485593 2021
3
Concurrent superior semicircular canal dehiscence and endolymphatic hydrops: A novel case series. 61
33421957 2021
4
Vestibular evoked myogenic potentials. 61
33483282 2021
5
[Superior semicircular canal dehiscence syndrome]. 61
33491628 2021
6
Superior semicircular canal dehiscence syndrome: Diagnostic criteria consensus document of the committee for the classification of vestibular disorders of the bárány society. 61
33522990 2021
7
Decision Making in Patients With Concomitant Otosclerosis and Superior Semicircular Canal Dehiscence: A Systematic Review of the Literature. 61
33065596 2021
8
Superior Semicircular Canal Dehiscence by Superior Petrosal Sinus: Proposal for Classification. 61
33605219 2021
9
Outcomes after mini-craniotomy middle fossa approach combined with mastoidectomy for lateral skull base defects. 61
33130529 2021
10
Beyond Tympanomastoidectomy: A Review of Less Common Postoperative Temporal Bone CT Findings. 61
33184072 2021
11
Traumatic superior semicircular canal dehiscence syndrome: case report and literature review. 61
33532052 2021
12
Elevated ocular VEMP responses in the absence of a superior semicircular canal dehiscence. 61
33130534 2021
13
Pulsatile Tinnitus in Superior Semicircular Canal Dehiscence Cured by Endovascular Coil Occlusion of the Superior Petrosal Sinus. 61
33394940 2020
14
Examination of the possible relation of the superior semicircular canal morphology with the roof thickness of the glenoid fossa and bone changes of the temporomandibular joint. 61
32458122 2020
15
How to do and why perform the skull vibration-induced nystagmus test. 61
33309493 2020
16
Concomitant Dehiscences of the Temporal Bone: A Case-Based Study. 61
33175590 2020
17
Current management of superior semicircular canal dehiscence syndrome. 61
32796272 2020
18
Stapes Surgery Outcomes in Patients With Concurrent Otosclerosis and Superior Semicircular Canal Dehiscence. 61
32472923 2020
19
MRI contribution for the detection of endolymphatic hydrops in patients with superior canal dehiscence syndrome. 61
32797276 2020
20
A Basis for Standardizing Superior Semicircular Canal Dehiscence Management. 61
32436400 2020
21
Thinning or dehiscence of bone in structures of the middle cranial fossa floor in superior semicircular canal dehiscence. 61
32044131 2020
22
Failure to close the gap: Concomitant superior canal dehiscence in otosclerosis patients. 61
31271445 2020
23
The Sensitivity of the cVEMP Test in Detecting A Superior Semicircular Canal Dehiscence and the Influence of a Coexisting Incudal Lysis: A Case Report. 61
32209523 2020
24
Bilateral superior semicircular canal dehiscence: bilateral conductive hearing loss with subtle vestibular symptoms. 61
32169981 2020
25
Temporal Bone Anatomy in Superior Semicircular Canal Dehiscence: A Case Control Study on Bone Pneumatization and the Level of Middle Cranial Fossa. 61
31821267 2020
26
Rhythmic Wave Patterns on Ambient Pressure Tympanometry in Patients With Objective Tinnitus-associated Pathologies. 61
31868782 2020
27
Quality of life outcomes after transmastoid plugging of superior semicircular canal dehiscence. 61
31761408 2020
28
Temporal bone histopathology: Superior semicircular canal dehiscence. 61
32128437 2020
29
A Case Series of Patients With Concurrent Otosclerosis and Superior Semicircular Canal Dehiscence. 61
31688614 2020
30
Superior Semicircular Canal Dehiscence Syndrome. 61
31986544 2020
31
Ocular Vestibular-Evoked Myogenic Potential Amplitudes Elicited at 4 kHz Optimize Detection of Superior Semicircular Canal Dehiscence. 61
32982915 2020
32
Case Report: Local Anesthesia Round Window Plugging and Simultaneous Vibrant Soundbridge Implant for Superior Semicircular Canal Dehiscence. 61
33414756 2020
33
Contribution of Reformatted Multislice Temporal Computed Tomography Images in the Planes of Stenvers and Pöschl to the Diagnosis of Superior Semicircular Canal Dehiscence. 61
31939882 2020
34
Bone-Conducted oVEMP Latency Delays Assist in the Differential Diagnosis of Large Air-Conducted oVEMP Amplitudes. 61
33193031 2020
35
Association between superior semicircular canal dehiscence and other dehiscences in temporal bone. 61
31886879 2020
36
Biomechanics of Third Window Syndrome. 61
32982922 2020
37
Changes in Vestibulo-Ocular Reflex Gain After Surgical Plugging of Superior Semicircular Canal Dehiscence. 61
32849185 2020
38
Ambient Pressure Tympanometry Wave Patterns in Patients With Superior Semicircular Canal Dehiscence. 61
32547469 2020
39
Vestibular Evoked Myogenic Potential (VEMP) Testing for Diagnosis of Superior Semicircular Canal Dehiscence. 61
32793102 2020
40
Validating the Utility of High Frequency Ocular Vestibular Evoked Myogenic Potential Testing in the Diagnosis of Superior Semicircular Canal Dehiscence. 61
31725592 2019
41
Superior semicircular canal dehiscence presenting with recurrent positional vertigo. 61
31699689 2019
42
Middle fossa approach for spontaneous cerebrospinal fluid fistula and encephaloceles. 61
31335556 2019
43
Electrocochleography: New Uses for an Old Test and Normative Values. 61
32271120 2019
44
Gauging the effectiveness of canal occlusion surgery: how I do it. 61
31668162 2019
45
Pressure Transmission to the Inner Ear by Mastoid Palpation After Transmastoid Surgery for Superior Canal Dehiscence. 61
31469801 2019
46
Superior semicircular canal dehiscence postoperative outcomes: A case series of 156 repairs. 61
31383473 2019
47
Why and when to refer patients for vestibular evoked myogenic potentials: A critical review. 61
31299589 2019
48
Outcomes of transmastoid resurfacing for superior canal dehiscence using a cartilage overlay technique. 61
30632156 2019
49
Skull vibration induced nystagmus in patients with superior semicircular canal dehiscence. 61
31029487 2019
50
CT evaluation of normal bone thickness overlying the superior semicircular canal. 61
31103254 2019
Sources

Variations for Superior Semicircular Canal Dehiscence

About this section
Sources

Expression for Superior Semicircular Canal Dehiscence

About this section
Search GEO for disease gene expression data for Superior Semicircular Canal Dehiscence.
Sources

Pathways for Superior Semicircular Canal Dehiscence

About this section
Sources

GO Terms for Superior Semicircular Canal Dehiscence

About this section

Biological processes related to Superior Semicircular Canal Dehiscence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron migration GO:0001764 9.26 TRIM46 NTN1
2 axonogenesis GO:0007409 9.16 TRIM46 NTN1
3 inner ear morphogenesis GO:0042472 8.96 NTN1 HMX3
4 negative regulation of axon extension GO:0030517 8.62 TRIM46 NTN1
Sources

Sources for Superior Semicircular Canal Dehiscence

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....